Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 71% of modeled bridge. Strengths: Occupancy Rate, Net-to-Gross Ratio. Risks: Bed Count. Risk-adjusted uplift: $16.1M (vs $22.5M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $8.6M | $8.6M | $0 | 12mo |
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $8.2M | $236K | $8.5M | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $1.3M | $3.9M | $5.2M | $16.4M | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $274K | $274K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 25.2% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Cost to Collect | $0 | $2.1M | $4.3M | $6.4M | $8.6M | $8.6M | $8.6M | $8.6M |
| Denial Rate Reduction | $0 | $2.1M | $4.2M | $6.4M | $8.5M | $8.5M | $8.5M | $8.5M |
| A/R Days Reduction | $0 | $1.7M | $3.5M | $5.2M | $5.2M | $5.2M | $5.2M | $5.2M |
| Clean Claim Rate | $0 | $137K | $274K | $274K | $274K | $274K | $274K | $274K |
| Cumulative | $0 | $6.1M | $12.3M | $18.3M | $22.5M | $22.5M | $22.5M | $22.5M |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $22.5M is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 86% / 22.5x | 91% / 25.4x | 95% / 28.2x | 97% / 29.6x | 99% / 31.1x |
| 9.0x | 81% / 19.6x | 86% / 22.2x | 90% / 24.7x | 92% / 26.0x | 94% / 27.2x |
| 10.0x | 77% / 17.3x | 81% / 19.6x | 85% / 21.9x | 87% / 23.1x | 89% / 24.2x |
| 11.0x | 73% / 15.5x | 77% / 17.6x | 81% / 19.6x | 83% / 20.7x | 85% / 21.7x |
| 12.0x | 69% / 13.9x | 74% / 15.8x | 78% / 17.7x | 80% / 18.7x | 81% / 19.6x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline 61% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 2.5x, adding 5.9 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $9.5M | — | $9.5M | 2.2% |
| Year 1 | $9.8M | +$15.0M | $24.9M | 5.8% |
| Year 2 | $10.1M | +$22.5M | $32.7M | 7.6% |
| Year 3 | $10.4M | +$22.5M | $33.0M | 7.7% |
| Year 4 | $10.7M | +$22.5M | $33.3M | 7.8% |
| Year 5 | $11.1M | +$22.5M | $33.6M | 7.8% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Cost to Collect | $4.3M | $6.4M | $8.6M | $10.3M |
| Denial Rate Reductio | $4.2M | $6.4M | $8.5M | $10.2M |
| A/R Days Reduction | $2.6M | $3.9M | $5.2M | $6.3M |
| Clean Claim Rate | $137K | $206K | $274K | $329K |
| Total | $11.3M | $16.9M | $22.5M | $27.0M |
Peer Context — Where This Hospital Sits
Key metrics vs 105 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | 2.2% | -8.3% | 4.1% | 14.6% | P45 |
| Net-to-Gross | 13.4% | 13.4% | 18.3% | 25.2% | P25 |
| Occupancy | 80.4% | 61.3% | 69.4% | 78.1% | P81 |
| Rev/Bed | $1.1M | $1.0M | $1.3M | $1.6M | P30 |
| Exp/Bed | $1.1M | $895K | $1.2M | $1.6M | P43 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.